Table 2 Association between left ventricular remodeling with CTO in hypertensive CAD patients.

From: Association between left ventricular remodeling and coronary chronic total occlusion in hypertensive coronary artery disease patients

Geometry patterns

CTO/Overall (%)

Model 1

Model 2

Model 3

OR

95%CI

P value

OR

95%CI

P value

OR

95%CI

P value

Normal geometry

61/1003 (6.1)

Reference

Reference

Reference

Remodeling

239/2427 (9.8)

1.801

(1.342, 2.418)

 < 0.001*

1.716

(1.275, 2.309)

 < 0.001*

1.696

(1.258, 2.285)

0.001*

 Concentric remodeling

49/709 (6.9)

1.123

(0.760, 1.659)

0.560

1.104

(0.746, 1.633)

0.622

1.095

(0.740, 1.622)

0.649

 Concentric LVH

100/1011 (9.9)

1.871

(1.336, 2.622)

 < 0.001*

1.798

(1.278, 2.528)

0.001*

1.798

(1.276, 2.535)

0.001*

 Eccentric LVH

90/707 (12.7)

2.617

(1.851, 3.700)

 < 0.001*

2.409

(1.697, 3.418)

 < 0.001*

2.355

(1.656, 3.349)

 < 0.001*

  1. Multivariable logistic regression models were fitted to estimate the odds ratio (OR) and 95% confidence interval (CI) for the association between LV remodeling and CTO. Three statistical models were used: Model 1 adjusted for age, gender, and body mass index (BMI); Model 2 further adjusted for smoking status, alcohol consumption, type 2 diabetes, controlled hypertension, low-density lipoprotein cholesterol (LDL-C), and acute coronary syndrome (ACS); Model 3 additionally adjusted for medications, including angiotensin receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs), calcium channel blockers (CCBs), thiazide diuretics, metoprolol, and angiotensin receptor neprilysin inhibitors (ARNI). LVH indicates left ventricular hypertrophy. *P < 0.05 indicates statistical significance.
Back to article page